Comanaging Thyroid Eye Disease: Proactive Care Approaches (CME Symposium)

To claim your credit, please click Register/Take Course.

Saturday, October 19, 2024
6:00 AM – 6:30 AM CT Registration and Breakfast
6:30 AM – 8:00 AM CT CME Symposium and Virtual Broadcast

Chicago Marriott Downtown Magnificent Mile

Salon 1, 7th Floor
540 Michigan Avenue
Chicago, Illinois

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review the possible clinical features and methods of clinical activity assessment in thyroid eye disease
  • Understand the most recent clinical data for teprotumumab, the only approved treatment for thyroid eye disease
  • Describe relevant clinical data for current treatments for thyroid eye disease
  • Select appropriate treatments for patients with thyroid eye disease across a spectrum of disease activity and duration
  • Apply guidelines for multidisciplinary management of teprotumumab-associated adverse effects
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
10/19/2024
Course expires: 
12/19/2024

Faculty

Andrew G. Lee, MD (Chair)
Herb and Jean Lyman Centennial Chair in Ophthalmology
Department of Ophthalmology
Blanton Eye Institute
Professor of Ophthalmology, Neurology, and Neurosurgery
Academic Institute
Full Clinical Member
Research Institute
Houston Methodist
Weill Cornell Medical College
Houston, Texas
Kenneth A. Beckman, MD, FACS
Clinical Assistant Professor of Ophthalmology
Ohio State University
Columbus, Ohio
Director of Corneal Surgery
Comprehensive Eye Care of Central Ohio
Westerville, Ohio
Amina I. Malik, MD
Associate Professor of Clinical Ophthalmology
Academic Institute
Houston Methodist
Weill Cornell Medical College
Chief of Oculoplastic and Reconstructive Surgery
Houston Methodist Eye Associates
Houston, Texas

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Kenneth A. Beckman, MD, is a consultant for AbbVie Inc, Alcon, Amgen, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Dompé US, Inc, Glaukos Corporation, Invirsa Ic, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation*, Ocular Science, Shenyang Sinqi Pharmaceutical Co, Ltd, Sun Pharmaceutical Industries, Inc, TearLab Corporation, Thea Pharma Inc, Verséa Health, Inc, Viatris Inc, Visus Therapeutics, and Yuyu  Pharma, Inc; is a contracted researcher for Glaukos Corporation; and has stocks or stock options in RxSIGHT.

Andrew G. Lee, MD, is a consultant for AstraZeneca and Bristol-Myers Squibb; is an advisory board member of Stoke Therapeutics and Viridian Therapeutics, Inc; and is on the speakers bureau for Alexion Pharmaceuticals Inc and Amgen Inc.

Amina I. Malik, MD, is a consultant for Amgen Inc.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Amgen Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of  MedEdicus LLC or Amgen Inc.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 331.2

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Please login if you already have an account on the MedEdicus Learning Portal OR Register to create an account and access the evaluation.